Cereno Scientific provides clarification regarding the trading suspension

By Modular Finance07:26 (UTC), 13 November 2026 Updated

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced a clarification regarding the trading suspension in its shares. A review conducted by the Company’s external legal advisors did not identify any improper conduct by the Company or its management in relation to the matters examined. Trading in the Company’s shares resumed today following a decision by Nasdaq.

On November 3, 2026, Nasdaq decided to suspend trading in Cereno Scientific’s shares with reference to undisclosed inside information.

At the Company’s initiative, its external legal advisors reviewed the Company’s and management’s handling of information in connection with the financing process and the trading suspension. The review was conducted independently of the Company’s management.

Through the announcement of the intended rights issue on November 12, 2026, Cereno Scientific has informed the market about the financing solution and the background to the decision.

With reference to the Company’s announcement, Nasdaq has decided to resume trading in Cereno Scientific’s shares today, November 13, 2026, with the normal opening procedure.

The Company cannot comment further on any external investigations or speculation regarding the circumstances surrounding the trading suspension.

About Cereno Scientific AB
Cereno Scientific is pioneering treatments to enhance and extend life. The company’s innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the fullest.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the underlying mechanisms of pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals in a Phase IIa trial in patients with PAH, including improvements in right heart function, functional class, risk score and patient quality of life, with early signs consistent with reverse vascular remodeling. An Expanded Access Program confirmed CS1 to be well-tolerated with a favorable safety profile over 12 months of treatment and showed that a majority of patients completing treatment maintained or improved clinical status. CS1 is currently being evaluated in EPIMODE, a global, placebo-controlled Phase IIb trial in PAH. CS014 is a new chemical entity and HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of a range of cardiovascular and pulmonary diseases with high unmet needs. CS014 showed a favorable safety and tolerability profile in Phase I, and is being advanced through a streamlined, FDA-aligned pathway toward Phase IIb in pulmonary hypertension associated with interstitial lung disease (PH-ILD). Cereno Scientific is also advancing the preclinical program CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist shown to prevent thrombosis without increased bleeding risk, currently being evaluated in antiphospholipid syndrome (APS).

The Company is headquartered in GoCo Health Innovation City in Gothenburg, Sweden, and has a US subsidiary, Cereno Scientific Inc., located in Kendall Square, Boston. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.